Methods and kits for predicting the sensitivity of a subject suffering of renal cancer to cancer treatment
AssigneesCentre National de la Recherche Scientifique (CNRS), Institut National De La Sante Et De La Recherche Medicale (Inserm)
InventorsGilles PAGES, Marc ETTAICHE, Emmanuel CHAMOREY, Maeva DUFIES, Sandy GUILIANO
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of predicting or monitoring the sensitivity of a subject having a tumor, in particular renal cell carcinoma (RCC) to a cancer treatment, to a method of selecting an appropriate treatment of cancer, to a method of screening or identifying a compound suitable for improving the treatment of a cancer, and to corresponding kits.
Claims14
An in vitro method of assessing the sensitivity of a subject having a renal cancer to an inhibitor of a tyrosine kinase receptor, or to an antibody selected from nivolumab, atezolizumab and avelumab, for treating renal cancer, which method comprises a step a) of determining, in a biological sample from said subject, the expression level of CXCL5 or CXCL7, and, when the CXCL5 or CXCL7 expression level is determined, a step b) of comparing said CXCL5 or CXCL7 expression level to a (CXCL5 or CXCL7) reference expression level, thereby assessing whether the subject having ccRCC is sensitive or resistant to the inhibitor of a tyrosine kinase receptor or to the antibody.
A method of selecting, for a subject having a renal cancer, a treatment comprising an inhibitor of a tyrosine kinase receptor or an antibody selected from nivolumab, atezolizumab and avelumab efficient against renal cancer in the subject, wherein the method comprises a step a) of determining the CXCL5 and/or CXCL7 expression level(s) in a biological sample of the subject having renal cancer before any administration to the subject of an inhibitor of a tyrosine kinase receptor or of an antibody selected from nivolumab, atezolizumab and avelumab, and a step b) of comparing said CXCL5 and/or CXCL7 expression level to (CXCL5 and/or CXCL7) reference expression level(s), CXCL5 and/or CXCL7 expression level(s) identical to the (CXCL5 and/or CXCL7) reference expression level(s) or below the (CXCL5 and/or CXCL7) reference expression level(s), being the indication that an inhibitor of a tyrosine kinase receptor or an antibody selected from nivolumab, atezolizumab and avelumab will not be efficient, or will not be efficient alone in the subject, and a step c) of selecting an appropriate treatment of renal cancer in the subject, for example combining said inhibitor of a tyrosine kinase receptor or said antibody with an additional compound such as a CXCL5 or CXCL7 antibody;
- and, on the contrary, a CXCL5 and/or CXCL7 expression level(s) above the (CXCL5 and/or CXCL7) reference expression level(s) being the indication that the inhibitor of a tyrosine kinase receptor or antibody will be efficient alone against renal cancer in the subject.
Use of a kit i) for assessing or monitoring the sensitivity or resistance of a subject having a renal cancer to an inhibitor of a tyrosine kinase receptor selected from sunitinib, axitinib, pazopanib, and sorafenib or to an antibody selected from nivolumab, atezolizumab and avelumab, and/or ii) for determining the potential toxicity of said inhibitor of a tyrosine kinase receptor or antibody in a subject having renal cancer, wherein the kit comprises detection means selected from the group consisting of at least CXCL5 polypeptide binding agent and/or CXCL7 polypeptide binding agent;
- a molecule allowing the binding agent detection;
- and, optionally, a leaflet providing the CXCL5 and/or the CXCL7 respective reference expression level(s).
Dependencies are inferred from the claim text.